Frequent amplification of AIB1, a critical oncogene modulating major signaling pathways, is associated with poor survival in gastric cancer.

摘要: // Jing Shi 1, * , Wei Liu Fang Sui 1 Rong Lu Qingyuan He 2 Qi Yang Hongjun Lv Bingyin Peng Hou Department of Endocrinology, The First Affiliated Hospital Xi’an Jiaotong University School Medicine, 710061, People’s Republic China Oncology, These authors have contributed equally to this work Correspondence to: Hou, e-mail: phou@mail.xjtu.edu.cn Keywords: gastric cancer, AIB1, genomic amplification, poor prognosis, signaling pathways Received: October 23, 2014      Accepted: April 17, 2015      Published: 29, 2015 ABSTRACT Amplified in breast cancer (AIB1) is a member p160 steroid receptor coactivator (SRC) family that mediates the transcriptional activities nuclear receptors and other transcription factors. It acts as major oncogene diverse cancers, whereas biological function AIB1 remains largely unclear. This study was designed explore role tumorigenesis its potential useful prognostic marker therapeutic target cancer. Our data demonstrated significantly up-regulated tissues compared with control subjects. Moreover, amplification found 47 133 (35.3%) cases, but not positively associated protein expression, correlated patient survival. knockdown cells dramatically inhibited cell proliferation, invasiveness tumorigenic nude mice, induced cycle arrest apoptosis. Mechanically, promotes survival through modulating such ErbB Wnt/β-catenin pathways. Collectively, these findings suggest plays an important pathogenesis represents for